Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

B cell targeted therapies.

Edward Keystone1

  • 1Department of Medicine, University of Toronto, Ontario, Canada. edkeystone@mtsinai.on.ca

Arthritis Research & Therapy
|June 18, 2005
PubMed
Summary
This summary is machine-generated.

B cells play a key role in rheumatoid arthritis (RA) inflammation. Therapies targeting B cells, like rituximab, show promise in clinical trials for treating RA patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and safety of CT-P47 versus reference tocilizumab: 32-week results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis, including 8 weeks of switching data from reference tocilizumab to CT-P47.

RMD open·2024
Same author

Pharmacokinetics and Safety of Intravenous Candidate Biosimilar CT-P47 and Reference Tocilizumab: A Randomized, Double-Blind, Phase 1 Study.

Journal of clinical pharmacology·2024
Same author

Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I study.

Expert opinion on biological therapy·2024
Same author

Impact of anti-rheumatic treatment on the individual components of the ACR composite score in patients with rheumatoid arthritis: real-world data.

Clinical and experimental rheumatology·2024
Same author

Having More Tender Than Swollen Joints Is Associated With Worse Patient-Reported Outcomes in Patients With Early RA.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2024
Same author

Having More Tender Than Swollen Joints is Associated With Worse Function and Work Impairment in Patients With Early Rheumatoid Arthritis.

ACR open rheumatology·2024

Area of Science:

  • Immunology
  • Rheumatology
  • Cell Biology

Background:

  • Rheumatoid arthritis (RA) pathogenesis involves multiple cell types, including B cells.
  • B cells are critical in maintaining the chronic inflammation characteristic of RA.
  • Understanding B cell involvement is key to developing novel RA therapies.

Purpose of the Study:

  • To evaluate the role of B cells in rheumatoid arthritis (RA) pathogenesis.
  • To review the efficacy of B cell-targeted therapies for RA treatment.
  • To assess the potential of B cell depletion and inhibition as therapeutic strategies for RA.

Main Methods:

  • Review of ongoing research on B cell populations in RA.
  • Analysis of clinical trial data for B cell-targeted therapies (rituximab, belimumab).

Related Experiment Videos

  • Assessment of treatment outcomes based on American College of Rheumatology (ACR) response criteria.

    • Main Results:

    • Rituximab combined with methotrexate demonstrated superior ACR 50% responses in RA patients compared to methotrexate monotherapy.
    • Belimumab treatment in a phase I trial led to significant reduction in CD20+ levels in systemic lupus erythematosus patients.
    • Clinical trials provide promising data for the efficacy of B cell-targeted treatments in RA.

    Conclusions:

    • B cell-targeted therapies represent a promising future therapeutic avenue for rheumatoid arthritis.
    • Depleting B cells (e.g., with rituximab) or inhibiting their stimulation (e.g., with belimumab) are viable strategies.
    • Further clinical investigation supports the role of B cell modulation in managing RA.